Can early UVB and steroids stop vitiligo in its tracks?
NCT ID NCT04843059
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether starting treatment early with UVB light therapy and low-dose steroids can stop vitiligo from spreading and improve skin color return. 51 people with different stages of vitiligo were treated for 6 months. Researchers took skin samples to see how immune cells changed. The goal is to find a way to prevent relapses, which happen in up to half of patients after repigmentation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
narrowband UVB light therapy and oral steroids (methylprednisolone)
What this could lead to
If successful, this approach could lead to better repigmentation and fewer relapses for people with vitiligo by targeting the immune cells in the skin early.
What could go wrong
This is a small, early-stage study (51 people) without a placebo group, so results may not apply to everyone. Steroids and UVB have side effects, and long-term benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Bordeaux
Bordeaux, 33440, France
-
CHU de Nice
Nice, alpes maritimes, 06001, France